Evaluation of SARS-CoV-2-Specific T-Cell Activation with a Rapid On-Chip IGRA
Source abstract
Abstract
Interferon-gamma release assays (IGRAs) that measure pathogen-specific T-cell response rates can provide a more reliable estimate of protection than specific antibody levels but have limited potential for widespread use due to their workflow, personnel, and instrumentation demands. The major vaccines for SARS-CoV-2 have demonstrated substantial efficacy against all of its current variants, but approaches are needed to determine how these vaccines will perform against future variants, as they arise, to inform vaccine and public health policies. Here we describe a rapid, sensitive, nanolayer polylysine-integrated microfluidic chip IGRA read by a fluorescent microscope that has a 5 h sample-to-answer time and uses ∼25 μL of a fingerstick whole blood sample. Results from this assay correlated with those of a comparable clinical IGRA when used to evaluate the T-cell response to SARS-CoV-2 peptides in a population of vaccinated and/or infected individuals. Notably, this streamlined and inexpensive assay is suitable for high-throughput analyses in resource-limited settings for other infectious diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: SARS-CoV-2 and COVID-19 Research · Biosensors and Analytical Detection · SARS-CoV-2 detection and testing
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Cellular and Molecular Diagnostics, Tulane University School of Medicine, New Orleans, Louisiana 70112, United States
Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, Louisiana 70112, United States
Department of Microbiology & Immunology, Tulane University School of Medicine, New Orleans, Louisiana 70112, United States
Department of Physics and Engineering Physics, Tulane University, New Orleans, Louisiana 70118, United States
Department of Psychiatry, Tulane University, New Orleans, Louisiana 70112, United States
Tulane Brain Institute, Tulane University, New Orleans, Louisiana 70112, United States
Funding
National Cancer Institute · National Institute of Allergy and Infectious Diseases · National Institute of Child Health and Human Development · U.S. Department of Defense · National Institute on Aging
References (59)
Show source-provided references
1. 10.1126/science.abf930210.1126/science.abf9302 ↗
2. 10.1016/j.ebiom.2022.10415810.1016/j.ebiom.2022.104158 ↗
3. 10.1056/NEJMoa211894610.1056/NEJMoa2118946 ↗
4. 10.1056/NEJMoa211659710.1056/NEJMoa2116597 ↗
5. 10.1016/j.eclinm.2021.10119010.1016/j.eclinm.2021.101190 ↗
6. 10.1136/bmj.n201510.1136/bmj.n2015 ↗
7. 10.1056/NEJMoa211945110.1056/NEJMoa2119451 ↗
8. 10.1093/cid/ciaa168510.1093/cid/ciaa1685 ↗
9. 10.1016/j.jinf.2020.04.03310.1016/j.jinf.2020.04.033 ↗
10. 10.3389/fcell.2020.0046810.3389/fcell.2020.00468 ↗
11. 10.1016/S1473-3099(20)30773-810.1016/S1473-3099(20)30773-8 ↗
12. 10.1016/j.vaccine.2016.02.06310.1016/j.vaccine.2016.02.063 ↗
13. 10.1126/sciimmunol.aan539310.1126/sciimmunol.aan5393 ↗
14. 10.1038/s41586-020-2550-z10.1038/s41586-020-2550-z ↗
15. 10.1038/s41467-021-24377-110.1038/s41467-021-24377-1 ↗
16. 10.1038/s41467-021-21856-310.1038/s41467-021-21856-3 ↗
17. 10.3201/eid2701.20361110.3201/eid2701.203611 ↗
18. 10.1172/JCI15017510.1172/JCI150175 ↗
19. 10.1182/blood.202101156810.1182/blood.2021011568 ↗
20. 10.1136/annrheumdis-2021-22064710.1136/annrheumdis-2021-220647 ↗
21. 10.1177/1756286421101283510.1177/17562864211012835 ↗
22. 10.1093/cid/ciab95410.1093/cid/ciab954 ↗
23. 10.1016/j.cell.2021.12.03210.1016/j.cell.2021.12.032 ↗
24. 10.1126/science.abg917510.1126/science.abg9175 ↗
25. 10.1016/j.tmaid.2021.10223410.1016/j.tmaid.2021.102234 ↗
26. 10.1038/s41586-021-04387-110.1038/s41586-021-04387-1 ↗
27. 10.1038/s41586-022-04460-310.1038/s41586-022-04460-3 ↗
28. 10.1016/j.diagmicrobio.2021.11557310.1016/j.diagmicrobio.2021.115573 ↗
29. 10.1093/infdis/jiab45810.1093/infdis/jiab458 ↗
30. 10.1016/j.jviromet.2021.11429510.1016/j.jviromet.2021.114295 ↗
31. 10.1007/s40121-021-00521-810.1007/s40121-021-00521-8 ↗
32. 10.1016/j.ijid.2021.09.07310.1016/j.ijid.2021.09.073 ↗
33. 10.1002/cti2.121710.1002/cti2.1217 ↗
34. 10.3201/eid2701.20377210.3201/eid2701.203772 ↗
35. 10.1016/j.cmi.2021.03.01010.1016/j.cmi.2021.03.010 ↗
36. 10.1093/cid/ciaa153710.1093/cid/ciaa1537 ↗
37. 10.1016/j.cmi.2020.09.05110.1016/j.cmi.2020.09.051 ↗
38. 10.1016/j.ijid.2021.02.03410.1016/j.ijid.2021.02.034 ↗
39. 10.1073/pnas.210348011810.1073/pnas.2103480118 ↗
40. 10.1021/acsnano.1c0662310.1021/acsnano.1c06623 ↗
41. 10.1039/D0LC01156H10.1039/D0LC01156H ↗
42. 10.1126/sciadv.abg490110.1126/sciadv.abg4901 ↗
43. 10.1021/acsnano.5b0039610.1021/acsnano.5b00396 ↗
44. 10.1021/acsnano.1c0437110.1021/acsnano.1c04371 ↗
45. 10.1021/acsnano.0c0301810.1021/acsnano.0c03018 ↗
46. 10.1021/nn406370u10.1021/nn406370u ↗
47. 10.1364/OL.30.00051010.1364/OL.30.000510 ↗
48. 10.1083/jcb.62.2.54010.1083/jcb.62.2.540 ↗
49. 10.2144/00011461010.2144/000114610 ↗
50. 10.1021/acs.jpcb.5b0155310.1021/acs.jpcb.5b01553 ↗
51. 10.1021/acs.jpcc.9b1087010.1021/acs.jpcc.9b10870 ↗
52. 10.1016/j.cca.2011.11.00610.1016/j.cca.2011.11.006 ↗
53. 10.1615/CritRevImmunol.v29.i3.1010.1615/CritRevImmunol.v29.i3.10 ↗
54. 10.1002/eji.20032427810.1002/eji.200324278 ↗
55. Tan J. T. · J. Immunol. · 1999 · 163 · 485910.4049/jimmunol.163.9.4859 ↗
56. 10.1021/acsnano.6b0206010.1021/acsnano.6b02060 ↗
57. 10.1021/acsnano.7b0116210.1021/acsnano.7b01162 ↗
58. 10.1021/nn403770610.1021/nn4037706 ↗
59. 10.1021/acsanm.1c0444310.1021/acsanm.1c04443 ↗